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Favism, that is G6PD deficiency, and drugs for Covid-19 
Amelia Carolina Sparavigna
Politecnico di Torino
A document, vital for people having Glucose-6-phosphate dehydrogenase deficiency (favism) is
available. The link is https://www.epicentro.iss.it/coronavirus/pdf/en-report-covid-19-14-2020.pdf .
In this document it is told that "Chloroquine and hydroxychloroquine currently applied to COVID-
19 patients should be avoided in those with severe G6PD deficiency as they could trigger a
hemolytic crisis in the patient". Other very important references are also given. Besides
Chloroquine and hydroxychloroquine, Primaquine and 8-Aminoquinolines are considered.
Torino - 17 May 2020.  DOI: 10.5281/zenodo.3831384
Favism is the popular name of the Glucose-6-phosphate dehydrogenase deficiency (G6PDD).
"It  is an inborn error of metabolism that predisposes to red blood cell breakdown. Most of the time,
those  who  are  affected  have  no  symptoms.  Following  a  specific  trigger,  symptoms  such  as
yellowish skin, dark urine, shortness of breath, and feeling tired may develop.  Complications can
include  anemia  and  newborn  jaundice.  Some  people  never  have  symptoms".  Wikipedia  -
https://en.wikipedia.org/wiki/Glucose-6-phosphate_dehydrogenase_deficiency
In Wikipedia it is also told that "About 400 million people have the condition globally.[1] It is
particularly common in certain parts of Africa, Asia, the Mediterranean, and the Middle East.[1]
Males are affected more often than females.[1] ... Carriers of the G6PDD allele may be partially
protected against malaria. [1]". To [1] corresponds link https://ghr.nlm.nih.gov/condition/glucose-6-
phosphate-dehydrogenase-deficiency . There we find: "An estimated 400 million people worldwide
have  glucose-6-phosphate  dehydrogenase  deficiency.  This  condition  occurs  most  frequently  in
certain  parts  of Africa,  Asia,  the Mediterranean,  and the Middle East.  It  affects  about  1  in  10
African American males in the United States".
It is clear that a large number of people suffering of favism can be also affected by Sars-Cov-2, and
therefore  have Covid-19.  A vital  document for  these persons is  available  at  the following link
https://www.epicentro.iss.it/coronavirus/pdf/en-report-covid-19-14-2020.pdf
The document is concerning the drugs used against Covid-19. It is entitled "Interim guidance for the
appropriate  support  of  people  with  enzymopenia  G6PD  (favism)  in  the  current  SARS-CoV-2
emergency scenario". Version April 14, 2020. The document has been prepared by the ISS COVID-
19 Rare Diseases Working Group. 
In the section entitled "G6PD enzymopenia and drugs for SARS-CoV-2". It is told that "The AIFA
has authorized the off-label use of some drugs, paid by the NHS, in derogation of Law 648/1996
such as the lopinavir / ritonavir association (and in the alternative darunavir in combination with
cobicistat  or  ritonavir)  and  chloroquine  or  hydroxychloroquine,  to  deal  with  the  pandemic
coronavirus  SARSCoV-2  in  the  absence  of  proven  treatment  ...  Both  chloroquine  and
hydroxychloroquine  can  have  serious  side  effects,  even  in  subjects  without  G6PD  deficiency,
especially  at  high  doses  or  in  combination  with  other  drugs.  They  must  not  be  used  without
prescription and without medical supervision, and the prescription in case of COVID-19 must refer
only to the case of clinical trials or protocols agreed at national level (EMA/170590/2020)".
The authors of the document are telling that we are facing a potential widespread of the use of these
drugs  to  all  symptomatic  patients.  "It  is  therefore  of  extreme  importance  to  recall  to  all  the
healthcare professionals to extend to all patients the warning relating to the use of chloroquine and
hydroxychloroquine,  in  case  of  presence  of  impaired  activity  of  the  glucose-6-phosphate
dehydrogenase  (G6PD).  People  with G6PD deficiency  have  greater  difficulties  in  metabolizing
oxygen free radicals (ROS), developing in some cases severe forms of hemolytic anemia". 
The  document  explains  that  the  "Hemolysis  is  determined  -  with  very  rare  exceptions  -  by  a
triggering factor such as the ingestion of fava beans and the intake of some drugs with intracellular
oxidizing action. Chloroquine and hydroxychloroquine are among these drugs, having an oxidizing
action. However, under normal conditions and in monotherapy, they do not give hemolysis, while
other  factors,  such as the patient's  immune status,  bacterial  or viral  infections,  the dose of the
oxidizing drug and / or drugs interaction may contribute to determine this effect. Therefore,  for
subjects  with  G6PD  deficiency,  SARS-CoV-2  infection  represents  an  additional  risk  factor.
Chloroquine and hydroxychloroquine currently applied to COVID-19 patients should be avoided in
those with severe G6PD deficiency as they could trigger a hemolytic crisis in the patient".
What  is  stressed  in  the  document  is  the  following.  "Consequently,  considering  that  the  G6PD
deficiency is an endemic condition in our country [Italy], and in order to guarantee the correct care
of SARS-Cov2 positive patients it is necessary to assure the condition of the G6PD status before
starting the pharmacological treatment with chloroquine or hydroxychloroquine, through a medical
history  and,  if  this  is  not  possible  and  depending  on  the  situation,  through  the  screening  or
quantitative test of the G6PD activity. It is necessary to keep in mind that the absence of previous
hemolytic crises in a person with G6PD deficiency does not lead to a reduction in risk, even in old
age".  The  document  is  also  considering  the  case  "if  the  treatment  with  chloroquine  or
hydroxychloroquine has already been started without the possibility to obtain timely a dosage of the
enzyme and  in  presence  of  both  a  drastic  drop in  hemoglobin  7  values,  ...  [see  details  in  the
document]  it is necessary to consider the presence of a deficiency of G6PD and to discontinue the
treatment".
Of course, the document is important for all people in the world.
Let us also consider primaquine. 
"G6PD  Deficiency  Prevalence  and  Estimates  of  Affected  Populations  in  Malaria  Endemic
Countries: A Geostatistical Model-Based Map" by Rosalind E. Howes, Frédéric B. Piel, Anand P.
Patil,  Oscar  A.  Nyangiri,  Peter  W.  Gething,  Mewahyu  Dewi,  Mariana  M.  Hogg,  Katherine  E.
Battle, Carmencita D. Padilla, J. Kevin Baird, and Simon I. Hay. "Primaquine is a key drug for
malaria elimination. In addition to being the only drug active against the dormant relapsing forms of
Plasmodium  vivax,  primaquine  is  the  sole  effective  treatment  of  infectious  P.  falciparum
gametocytes, and may interrupt transmission and help contain the spread of artemisinin resistance.
However, primaquine can trigger haemolysis in patients with a deficiency in glucose-6-phosphate
dehydrogenase (G6PDd). Poor information is available about the distribution of individuals at risk
of primaquine-induced haemolysis.  We present a continuous evidence-based prevalence map of
G6PDd and estimates of affected populations, together with a national index of relative haemolytic
risk".
Primaquine is mentioned in Eye Reports as used against Covid-19. 
https://www.eyereports.org/index.php/eyereports/article/view/99/PDF-EyeReports2020v6pS7  -  "A
recommendation for the use of chloroquine, hydroxychloroquine, primaquine, or tafenoquine for
prophylaxis  against  the  2019  novel  coronavirus  (COVID-19)  with  note  to  the  ophthalmic
considerations",  by Fouad Alshaban.
"With the ongoing pandemic of infectious disease termed coronavirus disease 2019 (COVID-19)
caused by the novel  coronavirus  identified  as  severe acute  respiratory  syndrome coronavirus  2
(SARS-CoV-2), prevention of infection and spread is critical in preventing morbidity and mortality.
Prophylaxis, specifically chemoprophylaxis, is particularly critical to breaking the spread and rapid
rate of increase of SARS-CoV-2.  Pre-exposure and post-exposure prophylaxis are both required
components of this public health measure.  As the use of anti-malarial agents, specifically the 4-
aminoquinolones, chloroquine and hydroxychloroquine, for the treatment of SARS-CoV-2 is now
being reported, attention must be turned to their role in the chemoprophylaxis of SARS-CoV-2.  In
a search of the peer-reviewed medical literature (using MEDLINE and cross-referenced literature),
this  report  is  first  peer-reviewed publication  to present  the  use of these anti-malarial  agents  as
prophylaxis  against  SARS-CoV-2"  In  the  text,  it  is  told  "Notably,  the  8-aminoquinolines  are
contraindicated in individual who have glucose-6phosphate dehydrogenase (G6PD) deficiency as
hemolytic anemia may occur and may be fatal". 
In "The friendly use of chloroquine in the COVID-19 disease: a warning for the G6PD-deficient
males  and for  the unaware carriers  of  pathogenic  alterations  of the G6PD gene",  by Ettore  D.
Capoluongo, Felice Amato,  and Giuseppe Castaldo,  it is told "The benefits of chloroquine therapy
strongly depend on: (i) the age of the patient; (ii) the clinical presentation and (iii) the stage of the
COVID-19  disease.  Noteworthy,  the  use  of  this  drug  is  contraindicated  in  some  conditions,
particularly the glucose-6-phosphate dehydrogenase (G6PD) deficiency. The latter is a condition
that has not been deeply taken into account particularly when, on the web, there has been a “viral”
spread of news emphasizing the safe use and the free availability of chloroquine". 
In the "G6PD deficiency in COVID-19 pandemic: “a ghost in the ghost” ", Sameer Al-Abdi and
Maryam  Al-Aamrid  tell  that  "There  are  about  350  million  people  with  glucose-6-phosphate
dehydrogenase (G6PD) deficiency worldwide. The highest prevalence of G6PD deficiency is in the
Arabian Peninsula and tropical Africa. ... Hydroxychloroquine has been proposed as a treatment for
COVID‐19 and clinical trials have been started evaluating this proposal. Hydroxychloroquine has
oxidative  properties  that  could  decrease  glutathione  levels  and may  cause  severe  hemolysis  in
G6PD-deficient patients. If hydroxychloroquine is found to be the silver bullet for COVID‐19, then
this may be a big challenge in treating COVID‐19 in G6PD-deficient patients. Accordingly, it is
prudent  to  use  additional  precautionary  measures  to  prevent  COVID-19  from reaching  G6PD-
deficient individuals".
In "COVID‐19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a
patient  with  glucose‐6‐phosphate  dehydrogenase  deficiency",   Yan  Beauverd,  Yannick  Adam,
Benjamin  Assouline,  Kaveh  Samii  tell  that  "Glucose‐6‐phosphate  dehydrogenase  (G6PD)
deficiency is an inherited genetic disorder caused by red cell enzymatic defects and is associated
with haemolytic crisis when patients are exposed to oxidative agents (fava beans, drugs, infections).
Hydroxychloroquine is suspected to trigger haemolytic crisis in G6PD‐deficient patients, and off‐
label administration of this drug to patients infected with the novel coronavirus (SARS‐CoV‐2)
could cause concern". In the article the authors report "the first case of severe haemolytic crisis in a
patient  with G6PD deficiency,  initiated by severe COVID‐19 infection and hydroxychloroquine
use. With worldwide spread of COVID‐19, especially in regions with a high prevalence of G6PD
deficiency, our case should alert physicians to this possible correlation".
Besides  the  drugs  used,  in  "Glucose-6-phosphate  dehydrogenase  deficiency  and  risk  of
cardiovascular disease: A propensity score-matched study", by Giovanni Mario Pes, Guido Parodi,
Maria Pina Dore, it is told that "G6PD deficiency is significantly associated with increased risk of
CVD (cardiovascular disease), although the underlying mechanisms are still poorly understood. The
loss of  important  protective  pathways against  oxidative  stress,  especially  in the early  stages of
atherogenesis, might play a crucial role".
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